Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

- Comprehensive Phase 2 Program to Provide Initial Proof-of-Concept Data

This Year -

SAN FRANCISCO, Jan. 7 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has enrolled the first patient in its Phase 2 clinical trial that utilizes Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET) to measure VIA-2291's ability to reduce vascular inflammation in treated patients. The company also provided a comprehensive update of its VIA-2291 Phase 2 clinical program.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiovascular events associated with inflammation, including heart attack and stroke. The FDG-PET trial is one of three concurrent, ongoing Phase 2 trials testing VIA-2291 in a variety of clinical settings. The Phase 2 clinical program's innovative trial designs are intended to provide new visibility to the role of inflammation in cardiovascular disease and the potential of VIA-2291 to address vascular inflammation.

"The continued momentum in our Phase 2 clinical program and the robustness of the trial designs put us on track to deliver critical proof-of-concept data for VIA-2291 later this year," said Lawrence K. Cohen, PhD, chief executive officer of VIA Pharmaceuticals. "Inflammation is the root cause of cardiovascular disease and there remains a significant unmet need to address the major adverse events, including heart attack and stroke,
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and ... of the  "North America Mammography Market - ...  report to their offering. ... a detailed type of imaging that customs ... A mammography exam, called a mammogram, is ...
(Date:5/27/2015)... Research and Markets ( ... the  "2015 Strategies in the European Hemostasis ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... pages, 120 tables, and is designed to ... identify and evaluate business opportunities emerging in ...
(Date:5/27/2015)... OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts ... a series of diverse complications arising from the presence ... tissues, which cause a rapidly progressing hyperactive host immune ... 50% depending on disease severity. The syndrome places a ... global marketplace, which for the purposes of this report ...
Breaking Medicine Technology:North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
... Dec. 20, 2011  As part of a national initiative, the ... with flu vaccination rates for staff of 90 percent or ... . "Increasing vaccination among health care workers is ... the health of all Pennsylvanians," said Secretary of Health Dr. ...
... SPRINGS, Fla., Dec. 20, 2011   Nutra Pharma Corporation ... for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy ... Executive Officer, Rik J. Deitsch, had published a Shareholder ... been very busy here at Nutra Pharma," explained Rik ...
Cached Medicine Technology:Pennsylvania Department of Health Lauds Health Care Facilities for Boosting Flu Vaccination Rates among Workforce 2Nutra Pharma Letter to Shareholders 2
(Date:5/27/2015)... Hills, CA (PRWEB) May 27, 2015 Khanna ... of the art web portal focussed on keratoconus eye ... This relentless progressive disease has its onset in the teenage ... down. The cornea or the front clear part of the ... the pressure in the eye. It results in poor vision ...
(Date:5/27/2015)... New York, New York (PRWEB) May 27, 2015 ... http://www.risperdallawsuit2014.com/ ) filed on behalf of individuals ... other complications related to the use of the ... mass tort litigation currently underway in Pennsylvania’s Philadelphia ... the litigation is proceeding with its bellwether trial ...
(Date:5/27/2015)... In today's healthcare landscape, where costs ... be challenging for doctors and hospitals to keep up ... , Austin-based HealthTronics, Inc. is offering a ... therapies for clinically sophisticated applications. The company has now ... Laser Ventures, Inc ., a mobile laser technology ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ... for enterprise organizations, announced today that SanMar Corporation ... its time, attendance and point tracking processes for ... United States. , Family-owned since 1971, Seattle-based ... retail, private label, and mill brands. SanMar supplies ...
(Date:5/27/2015)... Little Rock, AR (PRWEB) May 27, 2015 ... and Medix today announce a partnership to provide ... the Medix community. This collaboration seeks to strengthen ... skills measurement through CMSA’s CKP program. The mutually ... focused on identifying individual skills of talent in ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3
... of patients with hepatic granulomas have found sarcoidosis and ... granulomas, recent works have noted some patients with chronic ... associations. Today, patients that undergo liver biopsy often have ... possible anti viral therapy. The age of HIV and ...
... used for the relief of fever, headaches, and other ... NSAIDs are well documented and acetaminophen is accepted to ... effects of short-term, especially high-dose NSAID and acetaminophen use ... to be published on November 21 , 2008 in ...
... Dec. 29 Stereotaxis, Inc.,(Nasdaq: STXS ) ... and existing institutional investors to raise gross proceeds of ... in two separate,concurrent transactions. A portion of the warrants ... full, these warrants would provide an additional,approximately $10 million ...
... long-term complications of blood sugar disease, scientists say ... who have gastric bypass surgery not only lose weight ... study finds. , Also called bariatric surgery, the procedure ... thereby reducing the amount of food one can eat. ...
... day in the United States,approximately 10,000 babies are born. On ... across the country welcome their babies,into the world by offering ... Year.,Parents of 2009 New Year,s babies can go to ... Year,s Baby coupons for free Beech-Nut,foods. , ...
... Internet - , , ANTHEM, Ariz., Dec. 29 ... of its new web site at http://www.mychoicedentist.com and ... Phoenix , Arizona, area is proceeding successfully. "Arizona is ... CEO. "We anticipate expanding this service to almost every major ...
Cached Medicine News:Health News:May hepatic granulomas be part of the histological spectrum of chronic hepatitis C? 2Health News:Acute gastric injury due to high-dose analgesics? 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 3Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 4Health News:Gastric Bypass Halts Diabetes in Obese Teens 2Health News:Gastric Bypass Halts Diabetes in Obese Teens 3Health News:Beech-Nut Offers Free Food for Babies Born on January 1, 2009 2Health News:Beech-Nut Offers Free Food for Babies Born on January 1, 2009 3Health News:Prime Companies Announces Launch of New Dental Web Site 2
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... mid range space saver specular microscope. It has ... the corneal endothelium automatically. It also has the ... central area. The image of the cells is ... with the system., This model is exactly the ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... The JSZ Orthokeratology (oprifocon A) ... permeable contact lenses used for ... corrects nearsightedness (myopia). The patient ... removes them in the morning. ...
Medicine Products: